Why Lantern Pharma’s LP-300 data in EGFR L858R NSCLC could reshape the post-osimertinib debate
Lantern Pharma’s LP-300 showed an early EGFR L858R lung cancer signal. Read what the FDA meeting and trial redesign could change next.
Pharma & Biotech